Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet
Welcome to our third Field Note. As a reminder, Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug development, policy, and access.
In this Field Note, Josh discusses the busiest week in the psychedelics-as-therapeutics field to date, including:
- FDA’s final guidance for industry on clinical investigations of psychedelics
- A public meeting scheduled for September, hosted by FDA, that will examine the potential rollout of psychedelic therapies
- A NIDA grant awarded to researchers at Harvard to study ibogaine
- Eli Lilly’s planned acquisition of AtaiBeckley
Note: Our third Field Note is being made available for free. To receive all of our Field Notes, as well as our written coverage, Quarterly Briefing videos, and much more, subscribe to Pα+ today.
Once you click play, the episode may take a moment to load, depending on your internet connection and speed.
Thanks for listening to our third Field Note. I’m always keen to hear from our readers (and, listeners!), so do feel free to reach out to me via our contact page or via the voice message function below.
New: Send a voice message to Psychedelic Alpha.
You may now send brief voice messages to the Psychedelic Alpha editorial team. Your messages will be treated as anonymous unless you choose to include your name, affiliation, and/or contact information. We will not publish or otherwise distribute your recordings without your permission.